Tessera Defense and Homeland Security Inc.

The journey of BiomX is marked by significant milestones. In March 2024, BiomX made headlines with its acquisition of Adaptive Phage Therapeutics for $50 million. This strategic move was aimed at bolstering their clinical pipeline and advancing their lead product candidates through crucial Phase 2 clinical trials. The acquisition positioned BiomX as a leader in the phage therapy space, combining expertise and resources to tackle some of the most challenging bacterial infections.

BiomX's innovative approach and strategic decisions have attracted substantial investor interest. By 2025, the company had secured a total of $56 million through various funding rounds, including a notable $12 million raised in early 2025. These funds were pivotal in supporting the company's ambitious research and development goals, particularly in advancing treatments for conditions like cystic fibrosis.

Today, BiomX stands at the forefront of phage therapy innovation, driven by a commitment to transform the treatment landscape for bacterial infections. Their story is a testament to the potential of combining scientific ingenuity with strategic business acumen, paving the way for new therapeutic solutions in the fight against chronic diseases.